Study evaluates cryosupernatant for rodenticide coagulopathy in dogs

Retrospective data published in the Journal of Veterinary Emergency and Critical Care suggests cryosupernatant may be a workable transfusion option for dogs with suspected vitamin K antagonist rodenticide coagulopathy. In the seven-dog case series, drawn from a university teaching hospital’s records from 2000 to 2017, the median cryosupernatant dose was 11.0 mL/kg, prothrombin time improved significantly after transfusion, six dogs had resolution of clinical hemorrhage and were discharged, and no transfusion reactions were reported. All dogs also received vitamin K supplementation, while one dog was euthanized because of multi-organ dysfunction. The authors conclude that cryosupernatant could be considered as an alternative to fresh frozen plasma in this setting, despite its lower factor IX activity. (researchgate.net)

Why it matters: For veterinary professionals, the report adds a small but practical piece of evidence around blood product selection in emergency toxicology cases. Standard management of anticoagulant rodenticide toxicity centers on vitamin K₁ plus transfusion support when patients are actively bleeding or unstable, and Cornell’s diagnostic guidance specifically lists cryosupernatant among acceptable products for immediate factor replacement. That makes this paper less a practice-changing trial than an early signal that clinics with access to cryosupernatant, but limited fresh frozen plasma availability, may have another option when stabilizing hemorrhagic dogs. The biggest caveat is the evidence base: just seven retrospective cases, over a long study window, without a control group. (vet.cornell.edu)

What to watch: Whether larger comparative studies test cryosupernatant head-to-head against fresh frozen plasma, including cost, correction of coagulation times, bleeding control, and outcomes. (researchgate.net)